查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲高度活跃的原料药市场：分析与预测（2023-2033）
市场调查报告书
商品编码
1501635

欧洲高度活跃的原料药市场：分析与预测（2023-2033）

Europe Highly Potent API Market - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 65 Pages | 商品交期: 1-5个工作天内

价格

欧洲高活性 API 市场规模预计将从 2023 年的 59.8 亿美元增至 2033 年的 163.3 亿美元，预测期内复合年增长率为 10.57%。

推动高度活跃的原料药市场扩张的主要因素是癌症发生率的上升和原料药治疗应用的扩大。

主要市场统计数据
预测期 2023-2033
2023年评估 59.8亿美元
2033年预测 163.3亿美元
复合年增长率 10.57%

由于癌症发生率的增加以及 HPAPI 在各个治疗领域的应用不断扩大，欧洲高度活跃的 API 市场正在显着成长。该地区强大的製药业得到先进研发设施和严格法律规范的支持，促进了市场发展。欧洲主要企业正在大力投资製造能力和联合伙伴关係，以满足不断增长的需求。此外，创新技术和工艺的采用确保了高品质和安全的HPAPI的生产。此外，外包给专门的受託製造厂商（CMO）的趋势日益明显，这些组织是处理高活性化合物、确保安全和遵守环境法规以及降低製药公司营运成本的专家，这正在推动市场发展。

本报告调查了欧洲高度活跃的原料药市场，包括行业趋势、技术和专利趋势、法律制度、市场成长促进和限制、市场规模趋势和预测，以及主要国家的详细分析、竞争格局、主要企业简介等

目录

执行摘要

第一章 市场

  • 趋势：当前和未来的影响评估
    • 趋势 1：高效能 API 密封技术的进步
    • 趋势2：增加对高效能原料药生产单位的投资
    • 趋势3：製药公司将高效率原料药的生产外包给CDMO
  • 供应链/价值概述
    • 供应链及供应链风险
    • 价值链分析
  • 价格分析
  • 专利申请趋势（按年份/国家）
  • 监管状况
  • 全球重大事件的影响分析：COVID-19
  • 市场动态：概述
    • 市场驱动因素
    • 市场机会
    • 市场限制因素

第二章 区域

  • 区域概况
  • 欧洲
    • 区域概况
    • 市场成长推进因素
    • 市场问题
    • 法国
    • 德国
    • 英国
    • 西班牙
    • 义大利
    • 其他的

第三章市场：竞争基准化分析/公司简介

  • 下一个前沿
  • 地理评估
    • Almac Group
    • Axplora Group GmbH
    • BASF SE
    • CordenPharma International
    • Helsinn Healthcare SA.
    • ICROM
    • Lonza
    • Merck KGaA
    • Sterling Pharma SolutionsAlmac Group

第四章调查方法

Product Code: BHL2156SS

Introduction to Europe Highly Potent API Market

The Europe highly potent API market is projected to reach $16.33 billion by 2033 from $5.98 billion in 2023, growing at a CAGR of 10.57% during the forecast period 2023-2033. The primary factors propelling the expansion of the highly potent API market are the rising incidence of cancer, which boosts the demand for highly potent APIs, and the broadening range of therapeutic applications for these APIs.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$5.98 Billion
2033 Forecast$16.33 Billion
CAGR10.57%

Market Introduction

The Europe Highly Potent API market is experiencing significant growth, driven by increasing cancer prevalence and the expanding application of HPAPIs in various therapeutic areas. The region's robust pharmaceutical industry, supported by advanced R&D facilities and stringent regulatory frameworks, enhances market development. Key players in Europe are investing heavily in manufacturing capabilities and collaborative partnerships to meet the rising demand. Additionally, the adoption of innovative technologies and processes ensures the production of high-quality, safe HPAPIs. The market is further fueled by the growing outsourcing trend to specialized contract manufacturing organizations (CMOs) with expertise in handling highly potent compounds, ensuring compliance with safety and environmental regulations, and reducing operational costs for pharmaceutical companies.

Market Segmentation:

Segmentation 1: by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Competitive Strategy: The highly potent API market has numerous established players with product and service portfolios. Key players in the Europe highly potent API market analysed and profiled in the study involve established players offering products and services of highly potent API.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, type portfolio, and market penetration.

Some prominent names in the market include:

  • Almac Group
  • Axplora Group GmbH
  • BASF Pharma Solutions
  • CordenPharma International
  • Helsinn Healthcare SA.
  • ICROM
  • Lonza
  • Merck KGaA
  • Sterling Pharma Solutions

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Trend 1: Advancements in Containment Technologies for Highly Potent APIs
    • 1.1.2 Trend 2: Increasing Investment for Highly Potent API Manufacturing Units
    • 1.1.3 Trend 3: Pharmaceutical Companies Outsourcing Highly Potent APIs Production to CDMOs
  • 1.2 Supply Chain /Value Overview
    • 1.2.1 Supply Chain and Risks within the Supply Chain
    • 1.2.2 Value Chain Analysis
  • 1.3 Pricing Analysis
  • 1.4 Patent Filing Trend (by Year, Country)
  • 1.5 Regulatory Landscape
  • 1.6 Impact Analysis for Key Global Events - COVID-19
  • 1.7 Market Dynamics: Overview
    • 1.7.1 Market Drivers
      • 1.7.1.1 Increasing Incidence of Cancer Leading to Demand in the Adoption of Highly Potent APIs
      • 1.7.1.2 Advancements in Drug Delivery Technologies
      • 1.7.1.3 Expanding Therapeutic Applications of Highly Potent API
    • 1.7.2 Market Opportunities
      • 1.7.2.1 Growing Emphasis on Personalized Medicine
      • 1.7.2.2 Increasing Opportunities for Pharma Companies in Developing Markets
    • 1.7.3 Market Restraints
      • 1.7.3.1 Regulatory Complexity for Highly Potent APIs' Manufacturing
      • 1.7.3.2 High Development and Production Costs

2 Regions

  • 2.1 Regional Summary
  • 2.2 Europe
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
    • 2.2.4 France
    • 2.2.5 Germany
    • 2.2.6 U.K.
    • 2.2.7 Spain
    • 2.2.8 Italy
    • 2.2.9 Rest-of-Europe

3 Markets -Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers
  • 3.2 Geographic Assessment
    • 3.2.1 Almac Group
      • 3.2.1.1 Overview
      • 3.2.1.2 Key Developments
      • 3.2.1.3 Top Products/Product/Service Portfolio
      • 3.2.1.4 Top Competitors
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Axplora Group GmbH
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product/Service Portfolio
      • 3.2.2.3 Key Developments
      • 3.2.2.4 Top Competitors
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 BASF SE
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product/Service Portfolio
      • 3.2.3.3 Key Developments
      • 3.2.3.4 Top Competitors
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 CordenPharma International
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products/Product/Service Portfolio
      • 3.2.4.3 Key Developments
      • 3.2.4.4 Top Competitors
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Helsinn Healthcare SA.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products/Product/Service Portfolio
      • 3.2.5.3 Key Developments
      • 3.2.5.4 Top Competitors
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 ICROM
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products/Product/Service Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Key Personnel
      • 3.2.6.5 Analyst View
    • 3.2.7 Lonza
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products/Product/Service Portfolio
      • 3.2.7.3 Key Developments
      • 3.2.7.4 Top Competitors
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Merck KGaA
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products/Product/Service Portfolio
      • 3.2.8.3 Key Developments
      • 3.2.8.4 Top Competitors
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Sterling Pharma Solutions
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products/Product/Service Portfolio
      • 3.2.9.3 Key Developments
      • 3.2.9.4 Top Competitors
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Highly Potent API Market (by Region), $Billion, 2022-2033
  • Figure 2: Highly Potent API Market, Recent Developments
  • Figure 3: Highly Potent API Market: Value Chain Analysis
  • Figure 4: Highly Potent API Market: Pricing Analysis
  • Figure 5: Highly Potent API Market, Patent Analysis (by Year), January 2018-December 2023
  • Figure 6: Highly Potent API Market, Patent Analysis (by Country), January 2018-December 2023
  • Figure 7: Regulatory Framework for Highly Potent API
  • Figure 8: Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 9: Incidence of Cancer (by Region), Million, 2020-2040
  • Figure 10: Europe Highly Potent API Market, $Billion, 2022-2033
  • Figure 11: France Highly Potent API Market, $Billion, 2022-2033
  • Figure 12: Germany Highly Potent API Market, $Billion, 2022-2033
  • Figure 13: U.K. Highly Potent API Market, $Billion, 2022-2033
  • Figure 14: Spain Highly Potent API Market, $Billion, 2022-2033
  • Figure 15: Italy Highly Potent API Market, $Billion, 2022-2033
  • Figure 16: Rest-of-Europe Highly Potent API Market, $Billion, 2022-2033
  • Figure 17: Some of the Key Innovators in the Highly Potent API Landscape
  • Figure 18: Highly Potent API Market: Geographical Assessment
  • Figure 19: Strategic Initiatives, January 2021-December 2023
  • Figure 20: Share of Strategic Initiatives
  • Figure 21: Data Triangulation
  • Figure 22: Top-Down and Bottom-Up Approach
  • Figure 23: Assumptions and Limitations

List of Tables

  • Table 1: Europe Highly Potent API Market Snapshot
  • Table 2: Short-Term and Long-Term Opportunities and Risks (by Region)
  • Table 3: Key Trends, Impact Analysis
  • Table 4: Highly Potent API Market, Key Investment
  • Table 5: Recent Innovations for Manufacturing and Handling of Highly Potent Drugs
  • Table 6: Highly Potent API Market (by Region), $Billion, 2022-2033
  • Table 7: Highly Potent API Market (by Country), $Billion, 2022-2033